HC Wainwright Brokers Decrease Earnings Estimates for CNTB

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Stock analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Connect Biopharma in a note issued to investors on Thursday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($1.04) for the year, down from their prior forecast of ($0.90). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q4 2025 earnings at ($0.32) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.97) EPS, FY2028 earnings at ($0.80) EPS and FY2029 earnings at ($0.53) EPS.

CNTB has been the topic of a number of other reports. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Connect Biopharma in a research note on Thursday, November 13th. Wall Street Zen upgraded shares of Connect Biopharma to a “hold” rating in a research report on Friday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Connect Biopharma in a report on Wednesday, October 8th. Finally, Northland Capmk raised Connect Biopharma to a “strong-buy” rating in a report on Tuesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Connect Biopharma Stock Up 3.2%

CNTB stock opened at $2.57 on Monday. The firm has a market cap of $143.67 million, a price-to-earnings ratio of -3.52 and a beta of -0.14. The firm has a fifty day moving average price of $1.69 and a two-hundred day moving average price of $1.49. Connect Biopharma has a 1-year low of $0.51 and a 1-year high of $2.86. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.24 and a quick ratio of 7.24.

Connect Biopharma (NASDAQ:CNTB) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.07).

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Connect Biopharma during the 2nd quarter valued at $29,000. Koa Wealth Management LLC acquired a new position in Connect Biopharma in the second quarter valued at about $49,000. Finally, AlphaCore Capital LLC bought a new stake in shares of Connect Biopharma during the second quarter worth $78,000. 58.72% of the stock is owned by institutional investors.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.